Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up

Lenacapavir and the shift to NRTI-free, long-acting HIV treatment: implications for HBV patients

The article discusses the evolving HIV treatment landscape, focusing on the shift toward NRTI-free dual regimens and long-acting injectable

FDA Approves First 100% Effective HIV Prevention Drug with Global Impact

The article discusses the milestone approval of the first HIV prevention drug, lenacapavir (brand name Yeztugo), which offers 100% protectio

Correspondence: Nirmatrelvir–ritonavir suppresses viral load but may attenuate spike antibody response

This correspondence article discusses findings from the PANORAMIC trial published in The Lancet Microbe, showing that nirmatrelvir–ritonavir

Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy

Phase 1 trial finds triple monoclonal antibody combination safe and effective for HIV-1 prevention

This phase 1, multicentre, randomised, open-label trial (HVTN 140/HPTN 101 part B) evaluated the safety, pharmacokinetics, and neutralisatio

FDA Approves Shionogi's Oral Antiviral Ensitrelvir for COVID-19 Postexposure Prophylaxis

The FDA has approved ensitrelvir (Xocova), an oral antiviral developed by Shionogi, for preventing COVID-19 in people aged 12 and older who